Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Neutral protamine hagedorn insulin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Human Insulin Inhalation Powder | DRUG | patient specific, inhaled, at meals, 76 weeks |
| Neutral protamine hagedorn insulin | DRUG | patient specific dose, injected, daily, 76 weeks |
Inclusion Criteria: 1. Type 2 diabetes mellitus for at least 6 months 2. One or more oral antihyperglycemic medications for at least 12 weeks 3. HbA1c equal to or greater than 7.0%, and equal to or less than 10.5% 4. Nonsmokers, have not smoked for at least 6 months and agree not to smoke (cigars, ...
Neutral protamine hagedorn insulin is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is in Phase 2 clinical development, with one completed trial in Japan that enrolled 129 participants. The drug is not yet approved and remains under investigation.
Neutral protamine hagedorn insulin is being developed by Eli Lilly and Company, a biopharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus.
Neutral protamine hagedorn insulin is currently in Phase 2 clinical development. A Phase 2 trial for the drug has been completed, and it remains an investigational agent. It has not received regulatory approval and is still being evaluated for its potential use in treating Type 2 Diabetes Mellitus.
Neutral protamine hagedorn insulin has one completed clinical trial registered under NCT00490854, titled 'A Study for Patients With Type 2 Diabetes Mellitus.' This Phase 2 study was conducted in Japan, enrolled 129 participants aged 20 years and older, and included both male and female patients.
Yes, Neutral protamine hagedorn insulin is commonly known as NPH insulin. It is an intermediate-acting insulin formulation used to manage blood sugar levels. In the context of this clinical development program, it is being investigated as a treatment for Type 2 Diabetes Mellitus.